ConjuGon Scientific Advisory Board
Richard R. Burgess, Ph.D.
Dr. Burgess, ConjuGon's co-founder and the founder and former director of the University of Wisconsin Biotechnology Center, is one of the leading authorities on bacterial transcription, RNA polymerases and transcription factors. He received his Ph.D. in Biochemistry and Molecular Biology with Dr. James D. Watson at Harvard University. Dr. Burgess also has considerable business experience as a board member of six biotechnology and biomedical investment companies.
William A. Craig, M.D.
Dr. Craig, a UW-Madison Professor of Medicine and Pharmaceutics, is a leading expert in anti-microbial chemotherapy and the preclinical development of new anti-bacterials, especially those involving animal infection models. He is a former chair of the FDA Anti-Infectives Advisory Committee including their meetings on anti-microbial resistance and drug development.
James Dahlberg, Ph.D.
Dr. Dahlberg is the Frederick Sanger Professor of Biomolecular Chemistry at UW-Madison and a co-founder of Third Wave Technologies, a publicly-traded DNA diagnostics company. He is member of the National Academy of Sciences and American Academy of Arts and Sciences and served two terms on the Board of Governors of the American Academy of Microbiology. He has published over 150 scientific articles and holds 18 US and 5 foreign issued patents.
Richard Gamelli, M.D.
Dr. Gamelli is the Chairman of the Surgery Department and also the Director of the Burn and Shock Trauma Institute and the Burn Center at the Loyola University Medical Center near Chicago. He is a nationally recognized expert in the area of burns, shock and trauma and is currently the President of the American Burn Association. Dr. Gamelli has published over 175 peer-reviewed manuscripts, published and presented 125 abstracts, written 30 book chapters and edited 10 books.
Richard Proctor, M.D.
Dr. Proctor, an expert on Staphylococcal infections, is a UW-Madison Professor of Medical Microbiology and of Medicine and is an infectious disease specialist at the University of Wisconsin Hospital and Clinics. The work in his laboratory focuses on understanding the cellular and molecular basis of bacterial infections. He has served on a number of panels addressing emerging antibiotic resistance and was the President of the Wisconsin Chapter of the Infectious Diseases Society of America. He also was a founding member of the International Endotoxin Society and the co-founder of the Staphylococcal Diseases Gordon conference.
Molly Schmid, Ph.D.
Dr. Schmid, an expert in antibacterial drug development, is currently the Jacobs Visiting Professor at the Keck Graduate Institute of Claremont College, in Claremont, California. Previously she has held senior positions at Affinium Pharmaceuticals, Genencor International and at Microcide Pharmaceuticals. She is the author of more than 35 publications and holds eight U.S. patents with several additional patent applications pending. Dr. Schmid is a Fellow of the American Academy of Microbiology.
Christopher M. Thomas, Ph.D.
Dr. Thomas is Professor of Molecular Genetics in the School of Biological Sciences, and Director of the Graduate School, at the University of Birmingham, UK. He is one of the leaders in the field of bacterial plasmid biology. His research has mainly focused on various aspects of broad-host-range bacterial plasmids in Gram-negative bacteria – replication, transfer, stable inheritance, and control of gene expression. He did post-doctoral work with Donald Helinski at the University of California, San Diego. He recently completed his term as Editor-in-Chief of the Society for General Microbiology journal Microbiology. He earned his BA and PhD from the University of Oxford and is the author of more than 100 peer reviewed publications.
